Navigation Links
YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
Date:8/5/2010

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients. To date, 15 patients have been enrolled into the Phase II portion of the study. Given the favourable biological activity and safety data, the Company intends to expand the present program from 60 to 120 patients at up to six centers in the United States, Canada and Australia, subject to regulatory approval. Detailed safety and activity data for CYT387 are planned to be presented at the American Society of Hematology (ASH) meeting in Orlando, Florida in December this year.

Myelofibrosis is a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory due to both efficacy and safety concerns.

Dosing in the Phase I dose-escalation portion of the study commenced in November 2009. In total, 21 patients were treated across five dosing levels (100, 150, 200, 300 and 400mg daily for up to nine months). Reversible, dose-limiting toxicities (DLTs) were observed in two patients at the 400mg dose-level, namely an asymptomatic Grade 3 amylase and lipase elevation and a Grade 3 headache with both patients subsequently resuming treatment with CYT387 at reduced doses.

The m
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... "RegeneRx") today announced that it has received a ... Aging by Actin-Sequestering Peptides.  This patent includes claims ... and numerous other actin-sequestering peptides for these purposes.  ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... 19, 2011 New Report Added in ... to 2020 - Programmable Logic Devices (PLD) and Application Specific ...   Published by  GBI Research . ... 2020 Programmable Logic Devices (PLD) and Application Specific Standard Product ...
... about how certain kinds of bacteria make energy and synthesize ... team of scientists led by Donald Bryant, the Ernest C. ... research professor in the Department of Chemistry and Biochemistry at ... the journal Science on 16 December 2011, is ...
... The efficiency of conventional solar cells could be ... of solar energy conversion led by chemist Xiaoyang Zhu ... and his team have discovered that it,s possible to ... of sunlight using an organic plastic semiconductor material. ...
Cached Biology Technology:ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 3ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 4Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 2Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 3Discovery of a 'dark state' could mean a brighter future for solar energy 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... On Monday, August 17th at 1:30PM in Hensill Hall 113, ... AAAS in San Francisco will get to learn about the ... minds in the field. The symposium is called Good ... the Public. (Online link: http://www.sou.edu/aaaspd/2009SANFRANCISCO/Symposia09.html#15 ). As science ...
... another piece to the mounting body of evidence that ... arrest, "passive ventilation" significantly increases survival rates, compared to ... in an online edition of Annals of Emergency Medicine, ... cardiac arrest outside a hospital setting and were resuscitated ...
... 12, 2009) Research published online in the journal ... are associated with a 2.5-fold reduction in risk for neural ... brain and spinal cord, and the two most common NTDs ... Disease Control (CDC), an estimated 3,000 pregnancies in the U.S. ...
Cached Biology News:Science communication to take the stage at annual AAAS meeting in San Francisco 2Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Essential nutrient found in eggs may help lower risk of neural tube defects 2Essential nutrient found in eggs may help lower risk of neural tube defects 3
... pp65 Antigenemia Immunofluorescence Assay (IFA) is intended ... protein pp65 of CMV in isolated peripheral ... Erythrocyte Lysis Buffer - (Catalog ... of buffered ammonium chloride. (NH4CL) Fixation ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... samples for freezing point determinations. Includes built-in printer, keypad, and software for ... RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: